{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:38:02Z","timestamp":1777055882262,"version":"3.51.4"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008199","name":"RTI International","doi-asserted-by":"publisher","award":["7200AA18CA00040"],"award-info":[{"award-number":["7200AA18CA00040"]}],"id":[{"id":"10.13039\/100008199","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Nepal aims to eliminate lymphatic filariasis (LF) by 2030. Mass drug administration (MDA) has ceased in 53 of the 64 endemic districts. Following failure to pass the pre-Transmission Assessment Survey of antigenemia prevalence, five districts completed two rounds of MDA using a three-drug regimen (Ivermectin, Diethylcarbamazine, and Albendazole; IDA) and achieved over 65% coverage of the total population in 2023 and 2024. An Epidemiological Monitoring Survey (EMS) was conducted to evaluate IDA\u2019s impact. A cross-sectional EMS was conducted 9 months post-MDA in 11 evaluation units (EUs) across five districts, using two sites per EU (n\u2009=\u200922). A total of 6,829 individuals aged \u226520 years were sampled via multi-stage methods, with \u2265300 blood samples per site. Data on demographics and MDA participation were collected. LF antigen testing was followed by night blood microfilariae testing in antigen-positive samples. Analysis included non-parametric tests, logistic and mixed-effects models accounting for site-level clustering, and penalized regression (lasso and ridge) to assess predictor importance and manage multicollinearity. Nine of 11 EUs passed EMS. Two EUs in Kapilvastu failed due to \u22651% microfilariae prevalence in at least one site. Microfilariae prevalence was negatively correlated with site MDA coverage (p-value 0.04), but not antigen prevalence (p-value 0.8). Overall, 4.63% of participants were antigen-positive and 0.34% were microfilariae-positive (ratio 14:1). Being female (OR 0.12; 95% CI: 0.04\u20130.36) and participation in latest MDA round (OR 0.34; 95% CI: 0.15\u20130.77) were associated with lower microfilariae prevalence. Suboptimal impact of MDA was observed in two EUs based on microfilariae prevalence and may reflect insufficient treatment compliance. Two additional rounds of MDA with directly observed treatment are recommended to improve adherence. Female sex and participation in the most recent MDA round were associated with reduced odds of microfilaremia. Targeted strategies focusing on men and other identified risk groups may enhance program effectiveness.<\/jats:p>","DOI":"10.1371\/journal.pgph.0004809","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:45:29Z","timestamp":1777052729000},"page":"e0004809","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5006-6516","authenticated-orcid":true,"given":"Ram Kumar","family":"Mahato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokarna","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadu Chandra","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudra Prasad","family":"Marasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0087-3015","authenticated-orcid":true,"given":"David T. S.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-8890","authenticated-orcid":true,"given":"Kaliannagounder","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil Raj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak","family":"Sah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram Balak","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha","family":"Subedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshav Raj","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudip Raj","family":"Khatiwada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achut Babu","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saroj","family":"Mahaseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak Bahadur","family":"Mahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara R.","family":"Burgert-Brucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0792-3356","authenticated-orcid":true,"given":"Briana","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4441-9263","authenticated-orcid":true,"given":"Ashna","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4767-602X","authenticated-orcid":true,"given":"Satya Raj","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3090-6698","authenticated-orcid":true,"given":"Bhim Prakash","family":"Devkota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra Bhal","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna Prasad","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7104-5968","authenticated-orcid":true,"given":"Bhim Prasad","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-821X","authenticated-orcid":true,"given":"Bijay","family":"Bajracharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"12","key":"pgph.0004809.ref001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001366","article-title":"The emerging story of disability associated with lymphatic filariasis: a critical review","volume":"5","author":"LM Zeldenryk","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pgph.0004809.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006472","article-title":"Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects","volume":"12","author":"N Chandrasena","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pgph.0004809.ref003","unstructured":"World Health Organisation WHO. Global programme to eliminate lymphatic filariasis: progress report. 2025. https:\/\/www.who.int\/publications\/i\/item\/who-wer10040-439-449"},{"key":"pgph.0004809.ref004","unstructured":"Department of Health Services DO. Annual health report. Department of Health Services. 2022. https:\/\/censusnepal.cbs.gov.np\/results\/files\/result-folder\/NationalReport_English.pdf"},{"key":"pgph.0004809.ref005","first-page":"196","author":"World Health Organization","year":"2020"},{"issue":"11","key":"pgph.0004809.ref006","first-page":"951","article-title":"National Population and Housing Census 2021","volume":"6","year":"2021","journal-title":"Angewandte Chemie International Edition"},{"key":"pgph.0004809.ref007","unstructured":"Ministry of Health and Population. Lymphatic Filariasis Elimination Program [Internet]. kathmandu; 2017. Available from: https:\/\/www.edcd.gov.np\/uploads\/resource\/5b73f48db113a.pdf"},{"key":"pgph.0004809.ref008","unstructured":"Department of Health services(DoHS). Annual Report, Department of Health Services 2020\/21 [Internet]. 2022. Available from: https:\/\/dohs.gov.np\/content\/40\/annual-health-report-2077-78"},{"key":"pgph.0004809.ref009","unstructured":"World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: A Manual for National Elimination Programmes. 2011;1\u2013100."},{"key":"pgph.0004809.ref010","unstructured":"World Health Organization. World Health Organiszation Regional office south East Asia. 2023. Nepal Successfully Completes Mass Drug Administration Campaign aganist Lymphatic Filariasis in 15 Districts. Available from: https:\/\/www.who.int\/nepal\/news\/detail\/15-04-2023-nepal-successfully-completes-mass-drug-administration-campaign-against-lymphatic-filariasis-in-15-districts"},{"key":"pgph.0004809.ref011","unstructured":"Department of Health Services. Annual Health Report 2079\/80. Report [Internet]. 2024;1\u2013244. Available from: https:\/\/hmis.gov.np\/wp-content\/uploads\/2024\/02\/Annual-Health-Report-2079-80.pdf"},{"key":"pgph.0004809.ref012","unstructured":"World Health Organization. Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis [Internet]. Manual for national elimination programmes. 2025. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/44580\/9789241501484_eng.pdf?sequence=1&isAllowed=y"},{"key":"pgph.0004809.ref013","unstructured":"World Health Organization. Preventive Chemotherapy: Tools for improving the quality of reported data and information A field manual for implementation [Internet]. 2019. 141 p. Available from: (www.who.int\/neglected_diseases\/en"},{"key":"pgph.0004809.ref014","unstructured":"Department of Health Service. Annual Health Report [Internet]. 2024. Available from: https:\/\/doc-0c-24-prod-02-apps-viewer.googleusercontent.com\/viewer2\/prod-02\/pdf\/tb0vocvbmlr2i7kder2oafst318mbqgf\/vv72984o9757bfnrbptiu0tksqhngrl6\/1732383375000\/3\/112110811177192389440\/APznzabovnI6snt6YjXldch5zgjZQ0XRdEi_pIe_23YUXg8xrOK6QYPF3vUaebqd_yT4UXq"},{"issue":"6","key":"pgph.0004809.ref015","first-page":"2","volume":"90","year":"2021","journal-title":"Bioline Filariasis Test Strip"},{"key":"pgph.0004809.ref016","unstructured":"World Health Organization WHO. Bench Aids for the Diagnosis of Filarial Infections. 1997. https:\/\/iris.who.int\/bitstream\/handle\/10665\/37156\/9241544899_eng.pdf?sequence=1"},{"issue":"2","key":"pgph.0004809.ref017","article-title":"Wuchereria bancrofii microfilariae in paired samples of","author":"G Dreyer","year":"1996","journal-title":"Trop Med Int Heal"},{"issue":"3","key":"pgph.0004809.ref018","first-page":"139","article-title":"Regularization paths for Cox\u2019s proportional hazards model via coordinate descent","volume":"176","year":"2011","journal-title":"Physiol Behav"},{"issue":"5","key":"pgph.0004809.ref019","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/jcm9051550","article-title":"Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania","volume":"9","author":"AM Fimbo","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"pgph.0004809.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/ejhm.2002.18752","article-title":"Age and gender specific patterns of microfilaremia and circulating antigen with specific lymphocyte proliferative responses in Wucherereia bancrofti filariasis","volume":"9","author":"AA Al-Shafei","year":"2002","journal-title":"Egypt J Hosp Med"},{"issue":"3","key":"pgph.0004809.ref021","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1017\/S0950268899003702","article-title":"EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis","volume":"124","author":"RA Norman","year":"2000","journal-title":"Epidemiol Infect"},{"key":"pgph.0004809.ref022","article-title":"A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery","volume":"13","author":"GJ Weil","year":"2020","journal-title":"Int Health"},{"issue":"2","key":"pgph.0004809.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010096","article-title":"Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial","volume":"16","author":"L Tavul","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"pgph.0004809.ref024","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae019","article-title":"Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings","volume":"78","author":"A James","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pgph.0004809.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009069","article-title":"An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India","volume":"15","author":"P Jambulingam","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"19","key":"pgph.0004809.ref026","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"pgph.0004809.ref027","first-page":"44","article-title":"Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa","volume":"6","author":"PM Graves","year":"2021","journal-title":"Trop Med Infect Dis"},{"issue":"2","key":"pgph.0004809.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010096","article-title":"Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial","volume":"16","author":"L Tavul","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pgph.0004809.ref029","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1050","article-title":"Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in C\u00f4te d\u2019Ivoire: An Open-label Randomized Controlled Trial","volume":"71","author":"CM Bjerum","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pgph.0004809.ref030","article-title":"Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis","author":"G Pichon","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"issue":"7","key":"pgph.0004809.ref031","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1995-7645(11)60150-8","article-title":"A review of neglected tropical diseases: filariasis","volume":"4","author":"A Chandy","year":"2011","journal-title":"Asian Pac J Trop Med"},{"issue":"11","key":"pgph.0004809.ref032","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.pt.2019.08.003","article-title":"Evaluating the Evidence for Lymphatic Filariasis Elimination","volume":"35","author":"EL Davis","year":"2019","journal-title":"Trends Parasitol [Internet"},{"issue":"11","key":"pgph.0004809.ref033","article-title":"Diagnostics to support elimination of lymphatic filariasis-Development of two target product profiles","volume":"15","author":"KY Won","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pgph.0004809.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011942","article-title":"Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment","volume":"18","author":"SM Njenga","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pgph.0004809.ref035","doi-asserted-by":"crossref","first-page":"1297954","DOI":"10.3389\/fphar.2024.1297954","article-title":"Factors influencing implementation of mass drug administration for lymphatic filariasis elimination: a mixed-method study in Odisha, India","volume":"15","author":"P Ratna","year":"2024","journal-title":"Front Pharmacol"},{"key":"pgph.0004809.ref036","unstructured":"Gurung YB. Emerging issues of population ageing, keeping replacement level fertility and gender equality in Nepal. 2023."},{"key":"pgph.0004809.ref037","unstructured":"IOM. Migration in Nepal: a Country Profile 2019. Int Organ Migr [Internet]. 2019;155. Available from: https:\/\/publications.iom.int\/system\/files\/pdf\/mp_nepal_2019.pdf"},{"key":"pgph.0004809.ref038","unstructured":"RTI International. Improving Mda Using Qualitative. NTD TOOLBOX [Internet]. Available from: https:\/\/www.ntdtoolbox.org\/sites\/default\/files\/content\/paragraphs\/resource\/files\/2021-07\/Qualitative_Research_MDA_Guide"},{"issue":"12","key":"pgph.0004809.ref039","article-title":"Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after mass drug administration: Reducing \u201cnumber needed to test\u201d by targeting older age groups, hotspots, and household members of infected persons","volume":"14","author":"CL Lau","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pgph.0004809.ref040","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae021","article-title":"How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?","volume":"78","author":"K Kura","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pgph.0004809.ref041","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/inthealth\/ihad091","article-title":"Persons \u201cnever treated\u201d in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020-2021","volume":"16","author":"MA Brady","year":"2024","journal-title":"Int Health"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:45:39Z","timestamp":1777052739000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004809"}},"subtitle":[],"editor":[{"given":"Srinivasa Rao","family":"Mutheneni","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0004809","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}